AEON Biopharma announces leadership change amid growth strategy

Published 27/03/2025, 21:18
AEON Biopharma announces leadership change amid growth strategy

IRVINE, Calif. - AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical company, announced the resignation of its President and CEO Marc Forth, effective April 4, 2025. Forth will continue to serve on the company’s board of directors, providing strategic guidance. Jost Fischer, Chairman of the Board, will step in as interim CEO during the search for a permanent replacement.

The company, which is developing a botulinum toxin complex for various therapeutic indications, is currently progressing through a 351(k) biosimilar regulatory pathway. This process could potentially enable AEON to market its product, ABP-450, across all current and future therapeutic indications approved for BOTOX with a single FDA approval.

Fischer, who has been with AEON’s board since February 2017, acknowledged Forth’s significant contributions to the company’s growth strategy. He also expressed his commitment to advancing the ABP-450 program without interruption, emphasizing the company’s adequate cash balances to support upcoming FDA discussions in the second half of 2025.

AEON’s ABP-450, also known as prabotulinumtoxinA injection, is the same botulinum toxin complex marketed by Evolus under the name Jeuveau for cosmetic indications. It is manufactured by Daewoong in compliance with Good Manufacturing Practice and has been approved by regulatory authorities in the U.S., Canada, and Europe. AEON holds exclusive development and distribution rights for therapeutic indications of ABP-450 in various regions, including the United States and European Union.

The company has a seasoned management team with expertise in biopharmaceutical development and the commercialization of botulinum toxin products. AEON’s forward-looking statements reflect plans for future meetings with the FDA and the development of ABP-450 as a biosimilar to BOTOX.

This leadership transition news is based on a press release statement from AEON Biopharma.

In other recent news, AEON Biopharma, Inc. announced a 1-for-72 reverse stock split approved by its Board of Directors. This move aims to meet the NYSE American LLC compliance standards by elevating the company’s common stock price. The reverse stock split will take effect at the start of the trading day on February 26, 2025. Stockholders authorized this action during a Special Meeting, allowing a reverse stock split in a range of 1-for-5 to 1-for-150, with the Board finalizing the ratio at 1-for-72. The reverse stock split will not change the ownership percentage of stockholders, except for fractional shares, which will be rounded up. AEON Biopharma has filed the details of this stock split with the Securities and Exchange Commission in a Current Report on Form 8-K. This effort is part of AEON’s strategy to maintain its NYSE American listing by adhering to the exchange’s minimum share price requirements. These developments reflect AEON’s ongoing efforts to stabilize its market presence and ensure compliance with trading standards.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.